Objectives: Current pancreatic cancer diagnostics cannot reliably detect early disease or distinguish it from chronic pancreatitis. We test the hypothesis that optical spectroscopy can accurately differentiate cancer from chronic pancreatitis and normal pancreas. We developed and tested clinically compatible multimodal optical spectroscopy technology to measure reflectance and endogenous fluorescence from human pancreatic tissues.
P
ancreatic cancer is the third leading cause of cancer death in the United States, with a 5-year survival rate of only 7%, 1 in part because no clinical method currently exists to reliably diagnose the disease in its early stages. The current method of choice to detect early-stage pancreatic adenocarcinoma is endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), which has shown the potential to detect small tumors 2 but is hindered by wide variations in negative predictive value (NPV) (reported values vary from 16% to 96%). 2, 3 A recent meta-analysis of 28 clinical studies concluded that it was not advisable to use EUS-FNA to exclude the presence of cancer because "malignancy cannot be ruled out with adequate reliability." 3 Furthermore, EUS-FNA is unable to consistently distinguish pancreatic adenocarcinoma from chronic pancreatitis. 4 This key limitation is driven by the failure of current methods to provide reliable needle-based tissue sampling suitable for histology, as tissue architecture is essential to accurately characterize and differentiate inflammatory from neoplastic pancreatic mass lesions. In a prospective clinical study, the sensitivity (SE) of EUS-FNA for detecting pancreatic adenocarcinoma in the setting of chronic pancreatitis was only 54%. 4 Therefore, there is a significant clinical need to develop a method to more accurately detect and differentiate cancer and chronic pancreatitis.
Optical spectroscopy has shown potential to assist with clinical (pre-)cancer diagnostics in many organs and tissues, 5, 6 including needle-based in vivo diagnostics. 7, 8 The feasibility of tissue optical spectroscopy for characterizing human pancreatic disease has been demonstrated in ex vivo pilot studies. [9] [10] [11] [12] [13] Pancreatic tissue histology ( Fig. 1) illustrates some of the key morphological and biochemical changes that are typically associated with pancreatic cancer and chronic pancreatitis, relative to normal pancreas. These changes are expected to affect the manner in which incident light propagates through the tissue before returning to the surface, influencing the detected optical reflectance and fluorescence spectra.
Here, we report a clinically compatible optical spectroscopy technology and test the hypothesis that this technology can accurately distinguish between pancreatic cancer, chronic pancreatitis, and normal pancreatic tissue. The analysis of optical measurements from a medium as complex as human tissue, and the subsequent use of this optical data for tissue classification, is a challenging task due to the multifaceted information present in each measurement. Therefore, mathematical models 12,13 play a crucial role in optical detection of disease by extracting quantitative diagnostic parameters from the measured optical spectra of human tissues. Furthermore, biostatistical algorithms are critical for rigorously assessing the potential of new diagnostic techniques, because they can quantitatively assess diagnostic accuracy while also correcting for effects of correlations in the data set (such as the measurement of multiple tissue sites from each patient).
14 With these considerations in mind, our technology includes instrumentation for measuring optical reflectance and fluorescence, a Principal Component Analysis (PCA) model to analyze these complicated optical signals, and a set of biostatistical algorithms to rigorously test the ability of the optical method to accurately classify pancreatic tissues. By performing this ex vivo study, we were able to compare the results of our technique against the corresponding "criterion standard" histopathology readings obtained from the same tissue sites that we measured optically.
MATERIALS AND METHODS

Clinically Compatible Instrumentation
To acquire optical spectra from human pancreatic tissues, prototype clinically compatible investigational instrumentation was developed 10, 11, 15 and used. The instrumentation (Supplementary Fig. 1 , http://links.lww.com/MPA/A538) included 2 light sources: a continuous-wave tungsten-halogen lamp (HL 2000FHSA, Ocean Optics, Dunedin, Fla) for reflectance and a 355-nm laser (PNV001525-140, JDS Uniphase, San Jose, Calif) to excite tissue fluorescence. To deliver light to and collect light from the tissue surface, a custom fiber-optic probe (Ocean Optics) was used. The probe contained three fibers, each with diameter 660 μm, arranged in a triangular configuration ( Supplementary  Fig. 1 , http://links.lww.com/MPA/A538). One fiber delivered light from the lamp to the tissue, the second fiber delivered laser light to the tissue, and the third fiber collected light that returned to the tissue surface. The collected light was sent to a spectrograph (MS 125, Oriel Instruments, Stratford, Conn) and an intensified charge-coupled device (ICCD 2063; Andor Technology, Belfast, Northern Ireland) for wavelength-resolved detection. The reflectance and fluorescence measurements were performed sequentially, with data acquisition times less than 500 ms for reflectance and less than 1 s for fluorescence.
Acquisition of Optical and Histopathological Data
Reflectance and fluorescence spectra were acquired from freshly excised human pancreatic tissues within 30 minutes of FIGURE 1. Representative histology images of (A) normal pancreatic tissue, (B) chronic pancreatitis (inflammation), and (C) adenocarcinoma. Histopathological analysis shows increased stromal collagen (light pink stain) in adenocarcinoma and chronic pancreatitis (relative to normal pancreas), as well as morphological changes in cell nuclei (purple stain) in adenocarcinoma (relative to both normal pancreas and chronic pancreatitis). These biochemical and morphological changes in diseased tissues provide a useful source of endogenous contrast for optical disease detection in the pancreas. Scale bar = 50 μm. Editor's note: A color image accompanies the online version of this article. excision (Fig. 2) . The institutional review board of the University of Michigan approved the study (HUM00017352) and patient consent was obtained prior to all measurements. Multiple sites from each tissue specimen were measured, and 2 reflectance and 2 fluorescence measurements were acquired from each site (with the exception of 1 site, from which only 1 of each measurement was taken). For each measured site on each tissue specimen, biopsy and histopathology were performed to obtain the diagnostic "criterion standard." After the optical measurements were acquired at a given site, the fiber-optic probe was kept in position at that site to mark the location of the site until the pathologist was ready to perform a tissue biopsy of the site, and the biopsy was obtained by the pathologist immediately after the probe was removed. Biopsies were 3 to 5 mm in diameter, comparable to the~1-mm diameter region of tissue 16 interrogated by the fiber-optic probe. These tissue biopsies were subsequently fixed in formalin, paraffin-embedded, sectioned, stained with hematoxylin-eosin for histologic examination, and analyzed via histopathology. In all, 18 patients (39 normal sites, 34 pancreatitis sites, and 32 adenocarcinoma sites) were evaluated.
Data Preprocessing
Reflectance spectra for which the detected signal at 550 nm divided by the detected signal at 650 nm (R 550 /R 650 ) was less than 0.2 were removed from the data set because these spectra were dominated by absorption from blood. It is important to note that the presence of blood is not considered problematic in tissueoptics studies because blood can be avoided by repositioning the tip of the probe, 8 removed by suctioning the region of interest, 7 or accounted for mathematically. 12, 13 Fluorescence spectra with a signal-to-noise ratio (SNR) of less than 30 were also removed, because these spectra were considered too noisy to properly analyze. Prior to data analysis, all raw spectra were backgroundcorrected, corrected for instrument response, smoothed, and normalized to peak intensity. The resulting corrected spectra were used for data analysis.
Identification and Removal of Outlier Sites From the Data Set
A residual-based method 17 was used to detect and remove outlier sites for which the 2 measured fluorescence or reflectance spectra were extremely different from each other. This was done through a series of linear mixed models where the spectrum measurements at specific wavelengths were regressed on the tissue diagnosis with a random intercept to account for correlation among sites that originated from the same patient. Ten regressions were performed on the fluorescence spectra at wavelengths of 375. 18 10 used with permission) and patients and sites measured in this study. Mean reflectance spectra (B) and fluorescence spectra (C) from these measurements revealed significant differences between normal tissue, chronic pancreatitis, and adenocarcinoma. Error bars represent the standard error. Editor's note: A color image accompanies the online version of this article. For each of the regressions, the difference between the residuals of the 2 duplicate measurements at each site were calculated and ranked in order of magnitude. The ranks for the 10 regressions were then averaged to give an overall fluorescence or reflectance average rank for each site. Sites whose overall mean rank exceeded the 85th percentile of the total number of sites were flagged as potential outliers. Through this method 5 sites were identified as having a pair of very different reflectance spectra, and 4 additional sites were identified as having a pair of very different fluorescence spectra. Each site with 2 extremely different measurements was removed from the analysis (unless one of those two measurements had been removed from the data set previously due to low R 550 /R 650 value or low fluorescence SNR), and for the remaining sites, the two measured spectra were averaged. Of the 117 sites from which measurements were acquired, a total of 12 sites were removed from the data set due to low R 550 /R 650 value, low fluorescence SNR, or high degree of difference between the 2 reflectance or fluorescence measurements.
PCA Model
Differences among the tissue types were observed in both the reflectance and the fluorescence spectra (Figs. 2B and C). To quantitatively characterize these differences, a standard PCA model 18 was used to extract the principal components from each reflectance and fluorescence spectrum. The inputs to the PCA code were the corrected reflectance and fluorescence spectra after preprocessing and outlier removal were performed (see data preprocessing and outlier identification/removal paragraphs above), without any additional correction of the spectra for attenuation artifacts. The PCA code was written in MATLAB (Mathworks, Natick, MA) using functions that were built into the MATLAB programming language.
The first 3 reflectance and fluorescence principal components, their scores, and their statistical significance for distinguishing between the tissue types are displayed in Figures 3 and Supplementary Table 1 , http://links.lww.com/MPA/A539. The first reflectance principal component score (RPC1) and the first fluorescence principal component score (FPC1) were the most statistically significant ), distinguishing adenocarcinoma from chronic pancreatitis (P < 9 Â 10 −3 ), and distinguishing chronic pancreatitis from normal pancreatic tissue (P < 2 Â 10 ), and distinguishing chronic pancreatitis from normal pancreatic tissue (P < 5 Â 10 −3 (P < 0.01) for distinguishing adenocarcinoma from normal pancreatic tissue, distinguishing adenocarcinoma from chronic pancreatitis, and distinguishing chronic pancreatitis from normal pancreas.
Tissue Classification Algorithm-Statistical Methods
Selection of the variables used in the tissue classification algorithm was determined through multinomial logistic regression using generalized estimating equations (GEE) [19] [20] [21] to statistically account for the intrapatient correlations in the data arising from the fact that the data set included multiple tissue sites from each patient. GEE has been previously used in medical physics studies to correct for intrapatient correlations, 14, [22] [23] [24] for instance, in ophthalmology, in which there are correlations between data taken from each of the 2 eyes of a single patient.
14 However, optical methods for tissue classification typically do not account for statistical correlations between data obtained from multiple sites on a given patient. Here, we present an optics-based tissue classification algorithm that incorporates GEE to rigorously account for these intrapatient correlations, because we believe this to be a key improvement that should be widely adopted by the biomedical optics community. For tissue classification, a "leave-two-patientsout" cross-validation; 25 was used ( Supplementary Fig. 2 , http:// links.lww.com/MPA/A540).
Tissue Classification Algorithm-Selection Of Variables
For each variable extracted by the PCA model, a GEE model with an exchangeable correlation structure was used to contrast the differences between the mean values of that variable for each pair of tissue types. For each contrast, a Wald test statistic using the robust covariance matrix was calculated to account for the repeatedly measured observations from the same patients. 26 After the identification of significant predictor variables (Supplementary Table 1 , http://links.lww.com/MPA/A539), correlations between the selected variables were calculated and highly correlated variables were removed to minimize the multicollinearity.
The variables used in the algorithm that included reflectance and fluorescence were the scores of the first 3 reflectance principal components (RPC1, RPC2, RPC3), and the score of the first fluorescence principal component (FPC1). The score of the second fluorescence principal component (FPC2) was dropped due to extreme correlation with RPC2 (Pearson correlation = 0.76). The third fluorescence principal component FPC3 was dropped because it was not statistically significant for any of the tissue comparisons investigated in this study (Supplementary Table 1 , http:// links.lww.com/MPA/A539).
Tissue Classification Algorithm-"Leave-2-Patients-Out" Cross-Validation
The classification algorithm ( Supplementary Fig. 2 , http:// links.lww.com/MPA/A540) was run 9 times, and each time, the data set was split into a training set of 16 patients and a test set of 2 patients. The algorithm was executed 9 times because there were 18 patients overall, and each patient was put into the test set exactly once. In this way, the algorithm was always blinded to the patient data in the testing set. For each pair of training and test data sets, a standard multinomial logistic regression was fit to the training dataset, which is then used to generate optical diagnosis probabilities of adenocarcinoma, chronic pancreatitis, and normal tissue types for the observations in the test data set. Thresholds were then applied to these probabilities to determine the SE, specificity (SP), positive predictive value (PPV), NPV, and area under the receiver operating characteristic (ROC) curve for distinguishing cancer sites from noncancer (normal and chronic pancreatitis) sites. Ternary plots of the diagnosis probabilities of adenocarcinoma, chronic pancreatitis, and normal pancreas are shown in Supplementary Figure 3 
RESULTS
Variables from the PCA model were input into the tissue classification algorithm ( Supplementary Fig. 2 , http://links.lww.com/ MPA/A540) to distinguish between adenocarcinoma, chronic pancreatitis, and normal pancreas. The outputs of the classification algorithm were the optical diagnosis probabilities P(N), P(CP), and P(A) of each tissue site being normal, chronic pancreatitis, or adenocarcinoma. Ternary plots of the optical diagnosis probabilities P(N), P(CP), and P(A) were created for classification procedures that used both reflectance and fluorescence ( Supplementary  Fig. 3 , http://links.lww.com/MPA/A541), as well as reflectance only ( Supplementary Fig. 4(a) , http://links.lww.com/MPA/A542) and fluorescence only ( Supplementary Fig. 4(b) , http://links.lww. com/MPA/A542).
To determine the accuracy of the optical method for detecting pancreatic adenocarcinoma using reflectance and fluorescence PCA parameters, a threshold was applied to P(A). Specifically, a site was diagnosed as cancer if a manually defined threshold P(A) > 0.3 was met. The resulting SE, SP, PPV, and NPV for distinguishing adenocarcinoma from noncancerous tissues (Table 1) were calculated using cross-validation to be 91%, 82%, 69%, and 95%, respectively. The user-defined threshold on P(A) can be raised or lowered depending on whether the operator wishes to optimize the procedure for maximum SE or maximum SP. To demonstrate this concept, the SE and SP calculated for different thresholds on P(A) were used to generate ROC curves for distinguishing adenocarcinoma from non-cancerous tissues (Fig. 4) . The area under the ROC curve was 0.89 for the algorithm including both reflectance and fluorescence PCA parameters. These results show the high diagnostic accuracy of the optical method using both reflectance and fluorescence, as described in this report.
Additional variations of the classification algorithm were run to compare the results obtained by using only reflectance variables (RPC1, RPC2, RPC3) and only fluorescence variables (FPC1, FPC2) with those obtained by using a combination of reflectance and fluorescence variables (RPC1, RPC2, RPC3, FPC1). For these comparisons, thresholds were manually selected such that the resulting SE was the same (91%) for all 3 algorithms, and then the corresponding SP, PPV, and NPV of the 3 algorithms were compared.
Using only reflectance variables, and choosing the threshold of P(A) > 0.20 for cancer diagnosis, the SE, SP, PPV, and NPV for distinguishing adenocarcinoma from noncancerous tissues were 91%, 84%, 71%, and 95% (Table 1 ). The area under the ROC curve was 0.89 when only reflectance variables were used (Fig. 4) . Using only fluorescence variables, and choosing the threshold of P(A) > 0.22 for cancer diagnosis, the SE, SP, PPV, and NPV for distinguishing adenocarcinoma from noncancerous tissues were 91%, 78%, 65%, and 95% (Table 1 ). The area under the ROC curve was 0.86 when only fluorescence variables were used (Fig. 4) .
These results show that optical spectroscopy provided accurate classification of pancreatic disease. Interestingly, for distinguishing between the tissue types measured in this study, using reflectance alone provided essentially the same diagnostic accuracy as using reflectance and fluorescence combined (Table 1) . This is a significant finding, as an optical device that used only the reflectance modality would be less expensive, more compact, and faster when performing measurements.
DISCUSSION
In this study, we have developed and used clinically compatible optical spectroscopy technology to distinguish pancreatic cancer from noncancerous pancreatic tissues (normal and chronic pancreatitis). The tissue optical data were analyzed with a novel mathematical algorithm that combined PCA with a statistically rigorous tissue classification procedure. This technology was assessed, for the first time, on a set of 18 patients by using a "leave-2-out" cross-validation technique in which the classification results for each test set of 2 patients were compared with those of histopathology, as the diagnostic criterion standard. The optical method accurately classified pancreatic cancer sites, with a SE, specificity, PPV, and NPV of 91%, 82%, 69%, and 95%, respectively, with an area under the ROC curve of 0.89. These results suggest that optical spectroscopy has the potential to distinguish pancreatic cancer from nonmalignant pancreatic tissues to provide immediate diagnostic feedback in a clinical setting, because the data collection and analysis can be performed in a few seconds. This novel approach has the potential to revolutionize needlebased pancreatic tissue characterization and improve clinical diagnostics in this most challenging patient population. The technology could also be used surgically, using a handheld optical probe for tumor margin detection.
In this study, tissue classification using only reflectance provided nearly identical results to those obtained with a combination of reflectance and fluorescence. This finding can possibly be attributed to an overlap between the information encoded in the reflectance and fluorescence principal components. The reflectance data are known to contain notable information about tissue scattering, which is partially due to collagen in the tissue. However, collagen is also a prominent endogenous fluorophore in human pancreatic tissue, so the information about collagen is also found in the fluorescence spectra. Therefore, it is to be expected Results are shown for principal component analysis with reflectance and fluorescence together, reflectance only, and fluorescence only. The threshold P(A) > 0.3 was used to achieve the shown classification accuracy.
A indicates adenocarcinoma; CP, chronic pancreatitis; N, normal. that the reflectance and fluorescence principal components would include overlapping information. In Figure 3B , the first fluorescence principal component contains a spectral feature near the peak emission wavelength (~400 nm) of collagen fluorescence, which has been shown to distinguish between these tissue types in our previous work. 13 Figure 3A shows that the second and third reflectance principal components display spectral features similar to those of hemoglobin absorption, which has a distinctive Soret peak near 420 nm and secondary peaks near 545 and 575 nm. Because absorption (from hemoglobin) and scattering (from tissue components including collagen) play prominent roles in determining the measured reflectance spectrum, it makes sense that the first reflectance principal component could primarily include information about collagen scattering and the second and third reflectance principal components could primarily include information about hemoglobin absorption. Because the fluorescence spectrum also contains prominent information about collagen, as well as artifacts of hemoglobin absorption, it is quite possible that the fluorescence data are not providing a significant amount of diagnostic information that is different from that provided by the reflectance.
The diagnostic dilemma facing clinicians who care for patients with possible pancreatic disease is to accurately distinguish malignancy from chronic pancreatitis. Delay or failure to identify cancer contributes to the dismal survival rate associated with pancreatic adenocarcinoma. Using traditional methods of imaging, malignancy and inflammation share many histologic features, and the dense fibrosis observed in both conditions renders aspirated cells (cytology via FNA) insensitive in many clinical situations. In addition, chronic pancreatitis has different diagnostic and treatment strategies, so there remains intrinsic value to confirming an enigmatic diagnosis in the patient with severe, unexplained abdominal pain, where pancreatic disease remains a possibility.
This work has demonstrated for the first time that quantitative tissue optical spectroscopy using visible light can be used for classification of human pancreatic disease. Traditionally, the pancreas has been considered a challenging organ to study due to its location deep in the retroperitoneum and the lack of a noninvasive tissue criterion standard for comparison. Our study, using freshly excised surgical specimens containing the changes of both chronic pancreatitis and adenocarcinoma (as typically seen in this patient population) and the criterion standard of tissue histopathology, provides the scientific proof of principle for the potential role of optical tissue characterization of the pancreas in vivo. Current pancreatic cancer detection methods, which use ultrasound as the source of contrast, are unable to reliably detect the disease, 27 especially in the setting of concurrent inflammation (pancreatitis). 4 Our technique has the potential to provide significantly increased contrast to reliably detect pancreatic cancer by optically characterizing disease-related changes in the tissue. The innovative optical technology developed offers rapid data acquisition and analysis to provide immediate diagnostic feedback to the clinician, using statistically rigorous algorithms that can be tailored to the specific clinical question of interest (cancer vs noncancer, cancer vs pancreatitis, cancer vs normal, pancreatitis vs normal).
To establish the feasibility of clinical translation, we have addressed several limitations that must be overcome before the technology can be used clinically, either as an intraoperative tool for tumor margin detection or as an endoscopic tool for needlebased tissue diagnostics. The data analyzed in this study were from freshly excised human pancreatic tissues (ex vivo); therefore, the efficacy of the data analysis methods must be verified to be the same for in vivo human tissue. For minimally invasive applications, the technology must be incorporated into an endoscopic device that is compatible with the EUS procedure. Toward these goals, we have performed 3 important studies. First, we used tissue-simulating "phantoms" to verify the accuracy of our method for both an ex vivo fiber probe and an endoscope-compatible fiber probe. Second, we verified that the method extracted consistent values of ex vivo human pancreatic tissue morphology properties despite large variations in tissue blood content over time. These 2 studies provided further evidence that the method is translatable to in vivo human pancreatic tissue. Third, we conducted a pilot study to optically interrogate human pancreatic tissues in vivo during surgery. 28 Preliminary results from this in vivo study demonstrated that the optical method is able to extract the same diagnostically relevant tissue parameters from in vivo data as were extracted from ex vivo data, and that these parameters can be used to distinguish cancerous tissues from normal tissues in vivo in the same manner as they were used for ex vivo data.
The results of these studies will be used to appropriately inform the design of clinical optical diagnostic technology. We note that only data from normal, chronic pancreatitis, and adenocarcinoma sites were analyzed in the work reported here, although the methods could also be applicable to diagnosis of premalignant conditions and detection of cancer within a site containing several different tissue types. With this goal in mind, we conducted a pilot study that suggested the potential of the method to distinguish premalignant human pancreatic tissue sites from normal human pancreatic tissue sites. 29 In conclusion, we have presented an optical method for detection of pancreatic disease and used a rigorous biostatistical method to demonstrate its accuracy for classifying pancreatic cancer, chronic pancreatitis, and normal pancreatic tissue. By showing the ability to reliably detect pancreatic cancer and distinguish cancer from chronic pancreatitis, our method provides a potentially valuable inroad toward addressing an important unmet clinical need. The technology developed does not require the administration of exogenous contrast agents to patients and the portable clinical device is constructed with components at a reasonable manufacturing cost. Furthermore, our study suggests that it may be possible to streamline the device even further (in terms of cost, footprint, and data acquisition and processing time) by using only reflectance instrumentation, as using reflectance alone was shown to provide nearly identical diagnostic accuracy to using both reflectance and fluorescence. In addition to needle-based disease diagnosis, our technique is potentially applicable for rapid on-site detection of tumor margins during pancreatic surgery. Thus, our results provide the scientific "proof of principle" that the optical spectroscopic method described here has the potential to assist with the detection of pancreatic cancer, as well as chronic pancreatitis, in a clinical setting.
